Investment Thesis
Accuray is in financial distress with persistent operating losses (-10.6% margin), negative cash flow generation (-$14.8M FCF), and dangerously high leverage (3.48x debt-to-equity). While EPS improved 87.5% YoY, the company cannot cover interest from operations and faces liquidity pressure with only $38.1M cash against $145.2M long-term debt and negative interest coverage of -1.4x.
Strengths
- EPS improved 87.5% YoY, suggesting turnaround momentum from very negative base
- Gross margin of 25.4% demonstrates some product pricing power in medical device sector
- Current ratio of 1.42x provides near-term liquidity buffer despite negative cash flow
Risks
- Operating losses of $32M and negative operating cash flow (-$9.4M) indicate core business is destroying value
- Debt-to-equity of 3.48x with negative interest coverage (-1.4x) creates existential solvency risk
- Free cash flow negative at -$14.8M while cash reserves ($38.1M) insufficient relative to debt burden—potential covenant violation or refinancing crisis risk
Key Metrics to Watch
- Operating cash flow trajectory—must reach positive to validate turnaround; negative FCF unsustainable
- Interest coverage ratio and debt reduction progress—negative coverage is crisis-level
- Operating margin expansion path—company must reach operational profitability to de-risk leverage
Financial Metrics
Revenue
301.0M
Net Income
-47.3M
EPS (Diluted)
$-0.30
Free Cash Flow
-14.8M
Total Assets
447.6M
Cash
38.1M
Profitability Ratios
Gross Margin
25.4%
Operating Margin
-10.6%
Net Margin
-15.7%
ROE
-113.3%
ROA
-10.6%
FCF Margin
-4.9%
Balance Sheet & Liquidity
Current Ratio
1.42x
Quick Ratio
0.66x
Debt/Equity
3.48x
Debt/Assets
90.7%
Interest Coverage
-1.36x
Long-term Debt
145.2M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T06:58:12.922137 |
Data as of: 2026-03-31 |
Powered by Claude AI